At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
Leuprorelin Acetate Depot 3Mdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
In Brief
A Phase 4 clinical trial evaluating Leuprorelin Acetate Depot 3M for Central Precocious Puberty. Completed, enrolled 80 participants across 5 sites.
Detailed Summary
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Precocious Puberty
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMar 2023
Primary CompletionDec 2024
Study CompletionMar 2025
TodayJul 2026
First PostedApr 22, 2022
Enrollment StartMar 14, 2023
Primary CompletionDec 19, 2024
Study CompletionMar 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.2 years ago
Interventions
Leuprorelin Acetate Depot 3Mdrug
Leuprorelin Acetate Depot 3M SC injections.